Targeting cell signaling pathways for drug discovery: An old lock needs a new key

Journal of Cellular Biochemistry

Volumn 102, Issue 3, 2007, Pages 580-592

  Aggarwal, Bharat B ^a   Sethi, Gautam ^a   Baladandayuthapani, Veera ^a   Krishnan, Sunil ^a   Shishodia, Shishir ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TEXAS SOUTHERN UNIVERSITY   (United States)

Author keywords

Cancer; Cell signaling; Drug discovery; Natural products; Targeted therapy

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; BCR ABL PROTEIN; BEVACIZUMAB; BORTEZOMIB; CELECOXIB; CERIVASTATIN; CETUXIMAB; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; DACLIZUMAB; ERLOTINIB; ETANERCEPT; GEFITINIB; GEMCITABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; INFLIXIMAB; MINOXIDIL; PLACEBO; PROTEASOME INHIBITOR; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SILDENAFIL; THALIDOMIDE; TRASTUZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR;

ACNE LIKE RASH; ALLERGY; ARTHRITIS; BLOOD DISEASE; BLURRED VISION; BREAST CANCER; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CROHN DISEASE; DIARRHEA; DRUG COST; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FOLLICULITIS; GASTROINTESTINAL DISEASE; GENE MUTATION; HAIR GROWTH; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTENSION; INTERSTITIAL LUNG DISEASE; LEUKEMIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORTHOSTATIC HYPOTENSION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH DISEASE; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; THROMBOSIS;

ANIMALS; ANTIGENS, CD20; CHEMISTRY, PHARMACEUTICAL; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; HUMANS; HYPERTENSION; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 35048841732     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21500     Document Type: Review

References (65)

1. Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB. 2006. Anticancer potential of Silymarin: From bench to bed side. Anticancer Res 26:4457-4498.
2. Aggarwal BB. 2004. Nuclear factor-kappaB: The enemy within. Cancer Cell 6:203-208.
3. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. 2004. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res 24:2783-2840.
4. Aggarwal BB, Ichikawa H. 2005. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 4:1201-1215.
5. Aggarwal BB, Kumar A, Bharti AC. 2003. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res 23:363-398.
6. Aggarwal BB, Shishodia S. 2006. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71:1397-1421.
7. Albert A. 1968. A selective toxicity. Methuen & Co. London.
8. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J, Springer J. 1980. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl- coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 77:3957-3961.
9. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, Marz W, Reckless JP, Stein EA. 2003. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163:553-564.
10. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. 2006. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354:1021-1030.
11. Baylin SB, Ohm JE. 2006. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:107-116.
12. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, Wilson BA, Heller G, Sauter NP. 2006. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354:2006-2013.
13. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, Serbedzija G, Zimmermann GR, Foley MA, Stockwell BR, Keith CT. 2003. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 100:7977-7982.
14. Brunello N, Mendlewicz J, Kasper S, Leonard B, Montgomery S, Nelson J, Paykel E, Versiani M, Racagni G. 2002. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol 12:461-475.
15. Burtness B. 2007. Her signaling in pancreatic cancer. Expert Opin Biol Ther 7:823-829.
16. Campese VM. 1981. Minoxidil: A review of its pharmacological properties and therapeutic use. Drugs 22:257-278.
17. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648.
18. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242.
19. Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, Wexner SD, Giardiello FM. 2006. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 4:1035-1038.
20. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. 2004. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345.
21. Daub H, Specht K, Ullrich A. 2004. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 3:1001-1010.
22. Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, Dowden S, Levy R. 1999. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab. J Clin Oncol 17:1851-1857.
23. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA. 2006. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417.
24. Ehrlich P. 1913. Chemotherapeutics: Scientific principles, methods and results. Lancet 2:445-451.
25. Eiermann W. 2001. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data. Ann Oncol 12 (Suppl 1):S57-S62.
26. Ekstrand AJ, Sugawa N, James CD, Collins VP. 1992. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 89:4309-4313.
27. Fishman MC, Porter JA. 2005. Pharmaceuticals: A new grammar for drug discovery. Nature 437:491-493.
28. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J. 2003. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 Trial) [corrected]. J Clin Oncol 21:2237-2246.
29. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA Benson AB III. 2007. Bevacizumab in combination with oxaliplatin, Fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544.
30. Gschwind A, Fischer OM, Ullrich A. 2004. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer 4:361-370.
31. Hanahan DJ, Papahadjopoulos D. 1965. Interactions of phospholipids with coagulation factors. Thromb Diath Haemorrh Suppl 17:71-84.
32. Hopkins AL, Groom CR. 2002. The draggable genome. Nat Rev Drug Discov 1:727-730.
33. Howe GK, Clapp RW. 2004. Are we winning or losing the war on cancer? Deciphering the propaganda of nci's 33-year war. New Solut 14:109-124.
34. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342.
35. Hynes NE, Lane HA. 2005. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 5:341-354.
36. Ideker T, Galitski T, Hood L. 2001. A new approach to decoding life: Systems biology. Annu Rev Genomics Hum Genet 2:343-372.
37. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, Watanabe H, Saijo Y, Nukiwa T. 2006. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24:3340-3346.
38. Kaelin WG, Jr. 2005. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5:689-698.
39. Kaplan JC, Junien C. 2000. Genomics and medicine: An anti-cipation. From Boolean Mendelian genetics to multifactorial molecular medicine. C R Acad Sci III 323:1167-1174.
40. Keith CT, Borisy AA, Stockwell BR. 2005. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 4:71-78.
41. Kerns EH, Di L. 2003. Pharmaceutical profiling in drug discovery. Drug Discov Today 8:316-323.
42. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, Vokes EE. 2005. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23:8033-8040.
43. Kindler HL, Niedzwiecki D, Hollis D. 2007. A double-blind,placebo- controlled, randomized Phase III trial of gemcitabine, plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: A preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. "Gastrointest Ca Symposium: Multidisciplinary Approaches to the Prevention, Diagnosis, and Therapy of GI Cancers 2007 Program/Proceedings; Abstract 108."
44. Knowles J, Gromo G. 2003. A guide to drug discovery: Target selection in drug discovery. Nat Rev Drug Discov 2:63-69.
45. Krause DS, Van Etten RA. 2005. Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172-187.
46. Lindsay MA. 2003. Target discovery. Nat Rev Drug Discov 2:831-838.
47. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. 2002. The protein kinase complement of the human genome. Science 298:1912-1934.
48. Mencher SK, Wang LG. 2005. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin Pharmacol 5:3.
49. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. 2007. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966.
50. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ. 1995. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55:5536-5539.
51. Newman DJ, Cragg GM, Snader KM. 2003. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 66:1022-1037.
52. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, SutoT, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD. 2005. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672.
53. Reich DE, Lander ES. 2001. On the allelic spectrum of human disease. Trends Genet 17:502-510.
54. Renan MJ. 1993. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 7:139-146.
55. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. 2003. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617.
56. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. 2005. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684.
57. Salomon DS, Brandt R, Ciardiello F, Normanno N. 1995. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232.
58. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. 2006. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550.
59. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L. 2005. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132.
60. Shishodia S, Aggarwal BB. 2004. Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J Biol Chem 279:47148-47158.
61. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B. 2000. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952.
62. Tobert JA. 2003. Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2:517-526.
63. Valdivieso A, Valdes G, Spiro TE, Westerman RL. 1985. Minoxidil in breast milk. Ann Intern Med 102:135.
64. Warren E, Ward S, Gordois A, Scuffham P. 2004. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase. Clin Ther 26:1924-1933.
65. Yanovski SZ, Yanovski JA. 2002. Obesity. N Engl J Med 346:591-602.